NOVO B NOVO NORDISK A/S

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

Bagsværd, Denmark, 17 November 2025 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk.

1 Details of the person discharging managerial responsibilities/person closely associated
a)Name of the Board member/Executive/Associated PersonStephan Engels 
2 Reason for the notification 
a)Position/statusMember of the Board of Directors 
b)Initial notification/AmendmentInitial notification 
3 Details of the issuer 
a)NameNovo Nordisk A/S 
b)LEI549300DAQ1CVT6CXN342 
4 Details of the transaction(s) 
a)Description of the financial instrument,

type of instrument,
Shares



 
 Identification codeNovo Nordisk B DK0062498333 
b)Nature of the transactionPurchase of shares 
c)







Price(s) and volume(s)







 Price(s)Volume(s)  
 DKK 312.506,450  
     
d)Aggregated information
  • Aggregated volume
  • Price




6,450 shares

DKK 2,015,625.00
 
e)Date of the transaction2025-11-17 
f)Place of the transactionNasdaq Copenhagen 



Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 78,400 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit  , , , and .



Contacts for further information

Media: 
Ambre James-Brown







Liz Skrbkova (US)







Investors: 
Jacob Martin Wiborg Rode







Sina Meyer







Max Ung







Christoffer Sho Togo Tullin







Alex Bruce







Frederik Taylor Pitter







Company announcement No 36 / 2025

Attachment



EN
17/11/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on NOVO NORDISK A/S

 PRESS RELEASE

Novo Nordisk phase 2 trial with amycretin reports significant weight l...

Novo Nordisk phase 2 trial with amycretin reports significant weight loss and HbA1c reduction in type 2 diabetes Amycretin showed statistically significant weight loss of up to 14.5% at 36 weeksAmycretin demonstrated statistically significant reductions in HbA1c with up to 89.1% achieving HbA1c levels below 7%Amycretin appeared to have a safe and well-tolerated profile consistent with incretin and amylin-based therapies Bagsværd, Denmark, 25 November 2025 – Novo Nordisk today announced positive headline results from a phase 2 clinical trial with amycretin in people with type 2 diabetes. Th...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch